Yi-Long Wu
Co-led ADAURA and IPASS, the trials that made EGFR-targeted pills standard before and after surgery.
Yi-Long Wu is among the most cited lung cancer trialists in the world, co-principal investigator of ADAURA (adjuvant osimertinib) and a leader of IPASS, ADJUVANT-CTONG, and the Chinese Thoracic Oncology Group.
| Title | Journal | Year |
|---|---|---|
| Osimertinib in resected EGFR-mutated non-small-cell lung cancer (ADAURA) | NEJM | 2020 |
Pages like this
not linked directly; found by shared links- PersonPasi A. Jänne
Shares International Association for the Study of Lung Cancer, Osimertinib, EGFR, Non-small-cell lung cancer.
- TrialLAURA
Shares Osimertinib, EGFR, Non-small-cell lung cancer.
- PersonJean-Charles Soria
Shares Osimertinib, EGFR, Non-small-cell lung cancer.
- PersonShun Lu
Shares ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer, EGFR, Non-small-cell lung cancer.
- PersonHelena A. Yu
Shares Osimertinib, EGFR, Non-small-cell lung cancer.
- ProductGefitinib
Shares Guangdong Provincial People's Hospital, EGFR, Non-small-cell lung cancer.
- TrialFLAURA2
Shares Guangdong Provincial People's Hospital, Osimertinib, Non-small-cell lung cancer.
- PersonJie He
Shares ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer, Non-small-cell lung cancer.